MediVector, Inc. Awarded $138.5M to Advance Development of Emerging Infectious Diseases Medical Countermeasure Drug

MediVector, Inc., Boston, Mass., is being awarded a $138,500,000 cost-plus-fixed-fee contract for advance development of emerging infectious diseases medical countermeasure drug for the Federal Drug Administration licensure. Work will be performed in Boston, Mass., and is expected to be completed April 2016. Contract funds will not expire at the end of the current fiscal year. Solicitation was issued for full and open competition and four proposals were received. The Defense Threat Reduction Agency, Fort Belvoir, Va., is the contracting activity (HDTRA1-12-C-0031).

Read More.